Earth Science Tech (OTC: ETST), a diversified holding company, recently announced its Q1 2027 financial results for the period ended June 30, 2026. Key financial highlights included increases in revenue, gross profit, net income, and total assets, compared to the same period in fiscal year 2026 (“Q1 2026”). According to Giorgio R. Saumat, CEO and Chairman of the Board, Q1 2027 underscored the durability of the foundation ETST established in fiscal 2026, with the results reflecting “steady compounding progress and the inherent operating leverage within its business model” (https://ibn.fm/p9BPV).
The company recorded $9.0 million in revenue in Q1 2027, up from $8.8 million in Q1 2026, representing a 3% growth. Its gross profit increased 3.1% to $6.3 million in Q1 2027 from $6.1 million in Q1 2026, while its net income jumped 57% to $715,697 from $456,714 over the intervening period. The company also reported a 108.4% increase in operating cash flow to $707,131 from $339,376; its total assets grew 33.3% to $10.4 million in Q1 2027 from $7.8 million in Q1 2026.
Furthermore, all its key operating subsidiaries remained profitable. This has had the net effect of both strengthening ETST’s balance sheet and further diversifying its earnings base beyond one entity. Thus, compared to where the business was just a few years ago, Mr. Saumat explained, Q1 2027 further validates that Earth Science Tech’s strategic platform is becoming “increasingly efficient, diversified, and profitable.”
ETST also repurchased and retired more than 3.7 million shares, without adding debt to its balance sheet. This represents the company’s focus on returning significant value to its shareholders while remaining highly disciplined stewards of capital.
“Looking ahead, we are focused on scaling the business by expanding our geographic footprint, advancing our telehealth and pharmacy fulfillment platforms, and building long-term, sustainable shareholder value,” stated Mr. Saumat.
The company maintains rigorous internal standards and is actively focused on driving even greater operational efficiencies. At the same time, the company’s management is expanding its focus toward the capital markets to draw more institutional investors and ensure its public valuation reflects its financial success and future potential.
To that end, Earth Science Tech is exploring the possibility of purchasing and retiring Series B preferred stock, which holds super-voting powers, thus eliminating the existing dual-class voting structure that otherwise keeps institutional investors away. Earth Science Tech is also keen on uplisting to a higher-tier exchange, such as Nasdaq, NYSE, or OTCQX, with the company’s move to attract institutional investors being a part of this strategy.
The company also noted that the viability of these proposed strategies, as well as other matters relating to executive compensation and governance, is dependent on the outcome of the votes cast at the company’s 2026 Annual Meeting of Shareholders, scheduled for Monday, August 31, 2026 (https://ibn.fm/J1JSz).
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit…
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…